Market Place
Sourcing Support
Satellos to Present at Oppenheimer Annual Healthcare Conference
04 Feb 2025 //
BUSINESSWIRE
GondolaBio & n-Lorem Partner on ASO Therapies for Genetic Diseases
17 Dec 2024 //
BUSINESSWIRE
Satellos Announces Overnight Offering of Common Shares
16 Dec 2024 //
BUSINESSWIRE
Satellos Doses 1st Duchenne Muscular Dystrophy Patient in Trial
11 Dec 2024 //
BUSINESSWIRE
Satellos Joins Oppenheimer Rare Disease Summit
03 Dec 2024 //
BUSINESSWIRE
Satellos to Join Duchenne KOL Investor Webinar on Dec. 4, 2024
02 Dec 2024 //
BUSINESSWIRE
Satellos Reports Q3 2024 Financial Results & Clinical Update
13 Nov 2024 //
BUSINESSWIRE
Satellos` SAT-3247 Improves DMD Canines` Strength In Study
01 Oct 2024 //
BUSINESSWIRE
Satellos Doses First Participant in Phase 1 Study of SAT-3247
18 Sep 2024 //
BUSINESSWIRE
Satellos Announces Participation in September 2024 Investor Conferences
05 Sep 2024 //
BUSINESSWIRE
Satellos To Begin Phase 1 Trial With SAT-3247 After Regulatory Approval
19 Aug 2024 //
BUSINESSWIRE
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
12 Aug 2024 //
BUSINESSWIRE
Satellos Receives Rare Pediatric Disease Designation For SAT-3247
08 Aug 2024 //
BUSINESSWIRE
Satellos Submits Regulatory Filing For Phase 1 Trial Of SAT-3247
11 Jul 2024 //
BUSINESSWIRE
Satellos Presents Preliminary DMD Treatment Data For SAT-3247
02 Jul 2024 //
BUSINESSWIRE
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD)
27 Jun 2024 //
BUSINESSWIRE
Satellos: Advisory Board For Duchenne Muscular Dystrophy Drug Candidate
28 May 2024 //
BUSINESSWIRE
Satellos Announces Q1 2024 Results, Operational Highlights
14 May 2024 //
BUSINESSWIRE
Satellos Bioscience Announces Shareholder Meeting Results
14 May 2024 //
BUSINESSWIRE
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
05 Mar 2024 //
BUSINESSWIRE
Satellos Recognized as a Top 50 TSX Venture Exchange Company
21 Feb 2024 //
BUSINESSWIRE
Satellos to Commence Trading on the Toronto Stock Exchange
14 Feb 2024 //
BUSINESSWIRE
Satellos Announces Preliminary Data in Facioscapulohumeral Muscular Dystrophy
13 Feb 2024 //
BUSINESSWIRE
Satellos Announces Management Team Update
23 Jan 2024 //
BUSINESSWIRE
Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange
16 Jan 2024 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.